Goldberg IJ, Ginsberg HN (2006) Ins and outs modulating hepatic triglyceride and development of nonalcoholic fatty liver disease. Gastroenterology 130:1343–1346

Article  CAS  PubMed  Google Scholar 

Li Z et al (2023) Genetic association of lipids and lipid-lowering drug target genes with non-alcoholic fatty liver disease. eBioMedicine. https://doi.org/10.1016/j.ebiom.2023.104543

Article  PubMed  PubMed Central  Google Scholar 

Zhang X et al (2021) Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut 70:761–774

Article  CAS  PubMed  Google Scholar 

Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ (2018) Mechanisms of NAFLD development and therapeutic strategies. Nat Med 24:908–922

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anstee QM, McPherson S, Day CP (2011) How big a problem is non-alcoholic fatty liver disease? BMJ 343:d3897

Article  PubMed  Google Scholar 

Byrne CD, Targher G (2015) NAFLD: a multisystem disease. J Hepatol 62:S47–S64

Article  PubMed  Google Scholar 

Anstee QM, Targher G, Day CP (2013) Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10:330–344

Article  CAS  PubMed  Google Scholar 

Chalasani N et al (2018) The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67:328–357

Article  PubMed  Google Scholar 

Sheka AC et al (2020) Nonalcoholic steatohepatitis: a review. JAMA 323:1175–1183

Article  CAS  PubMed  Google Scholar 

Hishikawa D et al (2008) Discovery of a lysophospholipid acyltransferase family essential for membrane asymmetry and diversity. Proceed Nat Acad Sci 105:2830–2835

Article  CAS  Google Scholar 

Nilsson T, Jackson M, Peterson PA (1989) Short cytoplasmic sequences serve as retention signals for transmembrane proteins in the endoplasmic reticulum. Cell 58:707–718

Article  CAS  PubMed  Google Scholar 

Zhao Y et al (2008) Identification and characterization of a major liver lysophosphatidylcholine acyltransferase. J Biol Chem 283:8258–8265

Article  CAS  PubMed  Google Scholar 

Yan Y et al (2013) Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity 38:1154–1163

Article  CAS  PubMed  Google Scholar 

Jain S et al (2009) Characterization of human lysophospholipid acyltransferase 3. J Lipid Res 50:1563–1570

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rong X et al (2015) Lpcat3-dependent production of arachidonoyl phospholipids is a key determinant of triglyceride secretion. Elife. https://doi.org/10.7554/eLife.06557

Article  PubMed  PubMed Central  Google Scholar 

Zhang Q et al (2021) The structural basis for the phospholipid remodeling by lysophosphatidylcholine acyltransferase 3. Nat Commun 12:6869

Article  CAS  PubMed  PubMed Central  Google Scholar 

Demeure O et al (2011) Regulation of LPCAT3 by LXR. Gene 470:7–11

Article  CAS  PubMed  Google Scholar 

Rong X et al (2013) LXRs regulate ER stress and inflammation through dynamic modulation of membrane phospholipid composition. Cell Metab 18:685–697

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kakisaka K et al (2019) Caspase-independent hepatocyte death: A result of the decrease of lysophosphatidylcholine acyltransferase 3 in non-alcoholic steatohepatitis. J Gastroenterol Hepatol 34:1256–1262

Article  CAS  PubMed  Google Scholar 

Rong X et al (2017) ER phospholipid composition modulates lipogenesis during feeding and in obesity. J Clin Invest 127:3640–3651

Article  PubMed  PubMed Central  Google Scholar 

Henkel J et al (2012) Stimulation of fat accumulation in hepatocytes by PGE2-dependent repression of hepatic lipolysis, β-oxidation and VLDL-synthesis. Lab Investig 92:1597–1606

Article  CAS  PubMed  Google Scholar 

Kawahara K, Hohjoh H, Inazumi T, Tsuchiya S, Sugimoto Y (2015) Prostaglandin E2-induced inflammation: relevance of prostaglandin E receptors. Biochim Biophys Acta 1851:414–421

Article  CAS  PubMed  Google Scholar 

Burkett JB, Doran AC, Gannon M (2023) Harnessing prostaglandin E2 signaling to ameliorate autoimmunity. Trends Immunol 44:162–171

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang J et al (2024) Research progress, challenges and perspectives of phospholipids metabolism in the LXR‑LPCAT3 signaling pathway and its relation to NAFLD (Review). Int J Mol Med. https://doi.org/10.3892/ijmm.2024.5356

Article  PubMed  PubMed Central  Google Scholar 

Dana H et al (2017) Molecular mechanisms and biological functions of siRNA. Int J Biomed Sci 13:48–57

Article  PubMed  PubMed Central  Google Scholar 

Wang J, Lu Z, Wientjes MG, Au JL (2010) Delivery of siRNA therapeutics: barriers and carriers. AAPS J 12:492–503

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schroeder A, Levins CG, Cortez C, Langer R, Anderson DG (2010) Lipid-based nanotherapeutics for siRNA delivery. J Intern Med 267:9–21

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao S et al (2003) Galactosylated low molecular weight chitosan as DNA carrier for hepatocyte-targeting. Int J Pharm 255:57–68

Article  CAS  PubMed  Google Scholar 

Sato A, Takagi M, Shimamoto A, Kawakami S, Hashida M (2007) Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials 28:1434–1442

Article  CAS  PubMed  Google Scholar 

Weigel PH, Oka JA (1982) Endocytosis and degradation mediated by the asialoglycoprotein receptor in isolated rat hepatocytes. J Biol Chem 257:1201–1207

Article  CAS  PubMed  Google Scholar 

Zhang M et al (2013) Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma. J Control Release 168:251–261. https://doi.org/10.1016/j.jconrel.2013.03.020

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang W et al (2015) MiR-146b attenuates high-fat diet-ind